NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials. The Company has accelerated its drug
The post NanoViricides Nominates a Novel Candidate for COVID-19 Treatment appeared first on Pharma Mirror Magazine.
